BACKGROUND: An increase of the mean corpuscular volume (MCV) of erythrocytes and alterations in the lipid profiles have been described in HIV-infected patients under combination of anti-retroviral treatment (cART), particularly zidovudine (AZT). METHODS: In 687 sera from 179 HIV-positive patients, MCV levels were correlated with the clinical outcome or therapeutic effectiveness. The sera were classified into three groups according to AZT treatment; cART with AZT (n = 317), cART without AZT (n = 262), and no anti-retroviral therapy (n = 108). RESULTS: The MCV and lipid profile values were increased after cART. The AZT-based cART group had higher MCV levels (111.6 ± 7.0 vs. 97.8 ± 7.0 fl, P < 0.001) and a higher incidence of macrocytosis (>99 fl; 95.3% vs. 38.2%, P < 0.001) than the non-AZT-based cART group. The receiver operating characteristic curve analysis showed that the area under the curve was 0.835 and the cut-off of MCV (>102 fl) had a sensitivity of 96.1% and specificity of 66.7% for detecting HIV-RNA (-) sera in AZT-based cART group. In the multivariate regression analysis, HIV-viral load and HDL-cholesterol were the only significant correlates to the MCV values in the AZT-base cART group (P < 0.05). CONCLUSION: The MCV values could be used as a surrogate marker to monitor the clinical outcome of HIV-infected patients receiving AZT-based cART.
BACKGROUND: An increase of the mean corpuscular volume (MCV) of erythrocytes and alterations in the lipid profiles have been described in HIV-infectedpatients under combination of anti-retroviral treatment (cART), particularly zidovudine (AZT). METHODS: In 687 sera from 179 HIV-positive patients, MCV levels were correlated with the clinical outcome or therapeutic effectiveness. The sera were classified into three groups according to AZT treatment; cART with AZT (n = 317), cART without AZT (n = 262), and no anti-retroviral therapy (n = 108). RESULTS: The MCV and lipid profile values were increased after cART. The AZT-based cART group had higher MCV levels (111.6 ± 7.0 vs. 97.8 ± 7.0 fl, P < 0.001) and a higher incidence of macrocytosis (>99 fl; 95.3% vs. 38.2%, P < 0.001) than the non-AZT-based cART group. The receiver operating characteristic curve analysis showed that the area under the curve was 0.835 and the cut-off of MCV (>102 fl) had a sensitivity of 96.1% and specificity of 66.7% for detecting HIV-RNA (-) sera in AZT-based cART group. In the multivariate regression analysis, HIV-viral load and HDL-cholesterol were the only significant correlates to the MCV values in the AZT-base cART group (P < 0.05). CONCLUSION: The MCV values could be used as a surrogate marker to monitor the clinical outcome of HIV-infectedpatients receiving AZT-based cART.
Authors: H K Berthold; K G Parhofer; M M Ritter; M Addo; J C Wasmuth; K Schliefer; U Spengler; J K Rockstroh Journal: J Intern Med Date: 1999-12 Impact factor: 8.989
Authors: F J Palella; K M Delaney; A C Moorman; M O Loveless; J Fuhrer; G A Satten; D J Aschman; S D Holmberg Journal: N Engl J Med Date: 1998-03-26 Impact factor: 91.245
Authors: R M Gulick; J W Mellors; D Havlir; J J Eron; C Gonzalez; D McMahon; D D Richman; F T Valentine; L Jonas; A Meibohm; E A Emini; J A Chodakewitz Journal: N Engl J Med Date: 1997-09-11 Impact factor: 91.245
Authors: V Cambiano; F C Lampe; A J Rodger; C J Smith; A M Geretti; R K Lodwick; J Holloway; M Johnson; A N Phillips Journal: HIV Med Date: 2009-12-03 Impact factor: 3.180
Authors: Thomas Sternfeld; Antje Lorenz; Mathias Schmid; Angelika Schlamp; Hans Demmelmair; Berthold Koletzko; Johannes R Bogner Journal: Curr HIV Res Date: 2009-05 Impact factor: 1.581
Authors: S A Riddler; X Li; H Chu; L A Kingsley; A Dobs; R Evans; F Palella; B Visscher; J S Chmiel; Ar Sharrett Journal: HIV Med Date: 2007-07 Impact factor: 3.180
Authors: Asha R Kallianpur; Quan Wang; Peilin Jia; Todd Hulgan; Zhongming Zhao; Scott L Letendre; Ronald J Ellis; Robert K Heaton; Donald R Franklin; Jill Barnholtz-Sloan; Ann C Collier; Christina M Marra; David B Clifford; Benjamin B Gelman; Justin C McArthur; Susan Morgello; David M Simpson; J A McCutchan; Igor Grant Journal: J Infect Dis Date: 2015-12-21 Impact factor: 5.226